Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Innokeys
Singapore, Singaporeinnokeys.com ↗
- Ownership
- Private
- Employees
- ~25
- Development stage
- Other
01
Overview
Innokeys is a Singapore-based biotech company focused on oncology. It develops and commercializes innovations to address unmet needs, with its flagship asset being nimotuzumab, an anti-EGFR monoclonal antibody. Nimotuzumab is approved in over thirty countries for various solid tumors including head and neck, pancreatic, gastric, and cervical cancers, and the company coordinates its global late-stage clinical development and commercialization through partnerships.
- Therapeutic areas
- Oncology
- Modalities
- Monoclonal antibody
- Industry
- Biotech
02
Partnerships
InnoCIMABCIMAB
Beyond the preview
Go deeper on Innokeys.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Innokeys.